Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study

Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study

Background: The CDK4/6 inhibitor palbociclib combined with endocrine therapy (ET) has proven to prolong progression-free survival (PFS) in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC). Few data are available regar...

Full description

Bibliographic Details
Main Authors: Raffaella Palumbo, Rosalba Torrisi, Federico Sottotetti, Daniele Presti, Anna Rita Gambaro, Elena Collovà, Antonella Ferzi, Elisa Agostinetto, Cristina Maria Teragni, Giuseppe Saltalamacchia, Barbara Tagliaferri, Emanuela Balletti, Antonio Bernardo, Erica Quaquarini
Format: Article
Language:English
Published: SAGE Publishing 2021-03-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920987651

Internet

https://doi.org/10.1177/1758835920987651

Similar Items